Published online Sep 25, 2024. doi: 10.5501/wjv.v13.i3.96453
Revised: June 12, 2024
Accepted: July 10, 2024
Published online: September 25, 2024
Processing time: 113 Days and 11 Hours
Coronavirus disease 2019 (COVID-19) has been shown to increase the risk of stroke. However, the prevalence and risk of recurrent stroke in COVID-19 patients with prior stroke/transient ischemic attack (TIA), as well as its impact on mor
To evaluate the impact of COVID-19 on in-hospital mortality, length of stay, and healthcare costs in patients with recurrent strokes.
We identified admissions of recurrent stroke (current acute ischemic stroke admissions with at least one prior TIA or stroke) in patients with and without COVID-19 using ICD-10-CM codes using the National Inpatient Sample (2020). We analyzed the impact of COVID-19 on mortality following recurrent stroke admissions by subgroups.
Of 97455 admissions with recurrent stroke, 2140 (2.2%) belonged to the COVID-19-positive group. The COVID-19-positive group had a higher prevalence of diabetes and chronic kidney disease vs the COVID-19 negative group (P < 0.001). Among the subgroups, patients aged > 65 years, patients aged 45–64 years, Asians, Hispanics, whites, and blacks in the COVID-19 positive group had higher rates of all-cause mortality than the COVID-19 negative group
The study highlights the increased risk of all-cause in-hospital mortality in recurrent stroke patients with COVID-19, with a more pronounced increase in middle-aged patients, males, Hispanics, or Asians.
Core Tip: This study underscores the enhanced all-cause in-hospital mortality risk among recurrent stroke patients who test positive for coronavirus disease 2019 (COVID-19). Notably, the increased mortality risk is most significant in middle-aged individuals (45-64 years), males, and ethnic minorities, including Hispanics and Asians. Data from the National Inpatient Sample in 2020 revealed that COVID-19 patients with prior stroke or transient ischemic attack exhibit higher mortality compared to non-COVID-19 counterparts, alongside a greater prevalence of comorbidities such as diabetes and chronic kidney disease. These findings emphasize the critical need for targeted management strategies in these high-risk groups.
- Citation: Desai R, Mellacheruvu SP, Akella SA, Mohammed AS, Hussain M, Mohammed AA, Saketha P, Sunkara P, Gummadi J, Ghantasala P. Recurrent stroke admissions with vs without COVID-19 and associated in-hospital mortality: A United States nationwide analysis, 2020. World J Virol 2024; 13(3): 96453
- URL: https://www.wjgnet.com/2220-3249/full/v13/i3/96453.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i3.96453
Stroke poses a substantial health burden, affecting around 795000 people annually in the United States and ranking as a leading cause of long-term disability. Nearly 1 in 4 of these occur in patients with a history of stroke[1] i.e., approximately 25% of all strokes are recurrent[2]. There are several preventive strategies to reduce the risk of recurrent stroke, including medication and mitigating the risk factors[3]. Despite these preventive practices, the 5-year cumulative incidence of recurrent stroke remains relatively high, ranging from 16% to 30%[4,5]. Mohan et al[4], reported the cumulative risk of recurrence after first event stroke to be 3.1% at 30 days, 11.1% at 1 year, 26.4% at 5 years, and 39.2% at 10 years. To compo
The data utilized in this investigation were obtained from the National Inpatient Sample (NIS) (2020) database, an organization sponsored by the Agency for Healthcare Research and Quality. The NIS was provided with discharge data for over 7 million hospitalizations spanning 48 states by over 1000 hospital facilities[3]. This study focused on hospitalized individuals with recurrent stroke diagnoses.
Our study population was primarily composed of recurrent stroke hospitalizations. We divided these patients into two cohorts based on their COVID-19 test results: The COVID-19 positive (+) and COVID-19 negative (-) cohorts. A recurrent stroke was defined as any new acute ischemic stroke occurring with an onset separate from that of the index stroke or transient ischemic attack history. The primary outcome was in-hospital mortality. In addition, we conducted a subgroup analysis of in-hospital mortality by age, gender, and race. We evaluated demographics and baseline characteristics.
Descriptive statistics were utilized to analyze the demographics and comorbidities of the study population. We evaluated differences in baseline characteristics between the two cohorts using χ2 tests for categorical variables and the Mann-Whitney U test for continuous variables (non-normal distribution). The in-hospital mortality was determined using multivariable logistic regression analyses adjusted for potential confounders. The results were presented as adjusted odds ratios (aORs) with 95% confidence intervals (CI).
We found that there were 97255 hospitalizations due to recurrent strokes in the NIS database for the year 2020. Among recurrent stroke hospitalizations, 2140 (2.2%) belonged to the COVID-19 (+) cohort, and 95115 (97.8%) belonged to the COVID-19 (-) cohort. The COVID-19 (+) cohort predominantly comprised individuals aged 65 and above, accounting for 72.9% of cases. The proportion of COVID-19 + patients was greater in males (53.5%) compared to females (46.5%). When examining ethnicity, whites constituted the majority of the COVID-19 (+) cohort at 53.2%, blacks at 25.1%, Hispanics at 17.2%, and Asian/Pacific Islanders at 4.2%. Regarding socioeconomic status, those in the lowest income percentile (0–25) had the highest representation within the COVID-19 (+) cohort at 36.5%. Among healthcare facilities, urban teaching hospitals had the highest proportion of COVID-19 (+) cases at 75%, compared to urban non-teaching hospitals at 16.6% and rural hospitals at 8.4%. Moreover, patients with comorbidities such as diabetes (53.0%) and chronic kidney disease (CKD) (30.8%) were more frequently found within the COVID-19 (+) cohort compared to the COVID-19 (-) cohort (Table 1).
Variables | Total recurrent stroke (AIS with prior stroke/TIA) | P value | ||
No COVID-19 (n = 95115), % | COVID-19 (n = 2140), % | |||
Age in years at admission | Median (IQR) | 72 (62-82) | 73 (63-82) | 0.001 |
18-44 | 3.6 | 3.7 | ||
45-64 | 27.0 | 23.4 | ||
≥ 65 | 69.4 | 72.9 | ||
Sex | Male | 51.0 | 53.5 | 0.023 |
Female | 49.0 | 46.5 | ||
Race | White | 68.9 | 53.2 | < 0.001 |
Black | 19.3 | 25.1 | ||
Hispanic | 8.6 | 17.2 | ||
Asian/Pacific Islander | 2.8 | 4.2 | ||
Native American | 0.4 | |||
Median household income national quartile for patient ZIP code | 0-25th | 31.3 | 36.5 | < 0.001 |
26-50th | 27.1 | 30.1 | ||
51-75th | 23.1 | 18.0 | ||
76-100th | 18.4 | 15.4 | ||
Payer type | Medicare | 72.8 | 74.6 | 0.118 |
Medicaid | 10.2 | 9.0 | ||
Private | 17.0 | 16.4 | ||
Hospital location & teaching status | Rural | 6.7 | 8.4 | 0.001 |
Urban Nonteaching | 18.6 | 16.6 | ||
Urban Teaching | 74.7 | 75.0 | ||
Hospital region | Northeast | 14.5 | 16.8 | < 0.001 |
Midwest | 21.1 | 19.2 | ||
South | 45.2 | 47.9 | ||
West | 19.2 | 16.1 | ||
Comorbidities | ||||
Hypertension | 89.5 | 85.7 | < 0.001 | |
Diabetes | 43.2 | 53.0 | < 0.001 | |
Hyperlipidemia | 66.8 | 61.4 | < 0.001 | |
Obesity | 14.9 | 16.1 | 0.124 | |
Peripheral vascular disease | 11.7 | 8.6 | < 0.001 | |
Tobacco use disorder | 28.9 | 28.3 | 0.535 | |
Prior MI | 10.3 | 5.8 | < 0.001 | |
Prior VTE | 5.6 | 6.3 | 0.162 | |
Cancer | 5.0 | 3.7 | 0.009 | |
Chronic kidney disease | 22.7 | 30.8 | < 0.001 | |
Alcohol abuse | 4.3 | 2.8 | 0.001 | |
Drug abuse | 3.1 | 2.1 | 0.007 | |
Depression | 11.8 | 9.6 | 0.001 | |
Chronic pulmonary disease | 17.3 | 15.0 | 0.004 | |
Hypothyroidism | 15.2 | 14.0 | 0.133 | |
Other thyroid disorders | 2.3 | 2.1 | 0.502 | |
Valvular disease | 2.7 | 1.6 | 0.002 | |
Autoimmune conditions | 3.2 | 2.8 | 0.283 | |
Outcomes | ||||
All-cause in-hospital mortality | 4.0 | 22.9 | < 0.001 | |
Disposition of patient | Routine | 36.6 | 25.2 | < 0.001 |
Transfer to short-term hospital | 2.8 | 3.4 | ||
Transfer other: SNF, ICF, etc. | 38.6 | 49.7 | ||
Home health care | 21.9 | 21.8 | ||
Length of stay (days) | Median (IQR) | 3 (2-6) | 7 (3-13) | < 0.001 |
Hospital charges (USD) | Median | $52662 | $80888 | < 0.001 |
Patients in the COVID-19 (+) cohort showed poorer outcomes, with 49.7% requiring disposition to facilities like skilled nursing facility, intermediate care facility, etc., and 21.8% requiring home health care. The median length of stay was higher (7 days) for the COVID-19 (+) cohort compared to COVID-19 (-) (3 days). The median cost of hospitalization was also higher among the COVID-19 (+) cohort ($80888) compared to patients without COVID-19 ($52662) (all P-values < 0.005) (Table 1). Unadjusted all-cause mortality was substantially higher among recurrent stroke patients who belonged to the COVID-19 (+) cohort compared to COVID-19 (-) (22.9% vs 4.0%) (Table 1).
Using multivariate regression after adjusting for all factors and covariates, our analyses showed high in-hospital mortality among recurrent stroke patients with COVID-19 (+) (aOR: 7.01, 95%CI: 5.36–9.18). Subgroup analyses revealed higher odds among patients aged 45-64 (aOR: 8.4, 95%CI: 4.18-16.91) compared to age group 65 or greater (aOR: 7.04, 95%CI: 5.24-9.44); among males (aOR: 7.82, 95%CI: 5.38-11.35) compared to females (aOR: 6.15, 95%CI: 4.12-9.18). Although patients of all races exhibited significant adjusted odds of in-hospital mortality, Hispanics (aOR: 15.47, 95%CI: 7.61-31.44) and Asian Pacific Islanders (aOR: 14.93, 95%CI: 7.22-30.87) had almost three times more odds than Blacks (aOR: 5.73, 95%CI: 3.08-10.68), and White population (aOR: 5.54, 95%CI: 3.79-8.09) (All P value < 0.005) (Table 2).
In-hospital mortality | COVID-19 | Adjusted OR | 95%CI | P value | |
Lower Limit | Upper limit | ||||
Overall mortality | Yes vs No | 7.01 | 5.36 | 9.18 | < 0.001 |
In-hospital mortality by individual subgroup | |||||
Ages 45-64 | Yes vs No | 8.4 | 4.18 | 16.91 | < 0.001 |
Ages 65 and above | Yes vs No | 7.04 | 5.24 | 9.44 | < 0.001 |
Male | Yes vs No | 7.82 | 5.38 | 11.35 | < 0.001 |
Female | Yes vs No | 6.15 | 4.12 | 9.18 | < 0.001 |
Whites | Yes vs No | 5.54 | 3.79 | 8.09 | < 0.001 |
Blacks | Yes vs No | 5.73 | 3.08 | 10.68 | < 0.001 |
Hispanics | Yes vs No | 15.47 | 7.61 | 31.44 | < 0.001 |
Asian/Pacific Islanders | Yes vs No | 14.93 | 7.22 | 30.87 | < 0.001 |
Hospitalizations for recurrent strokes in patients who also tested positive for COVID-19 were associated with higher mortality rates longer stays in the hospital and increased total healthcare costs. Within the COVID-19 (+) cohort, it was observed that men, individuals in middle age, as well as Hispanic and Asian patients, faced a greater risk of in-hospital mortality.
Our findings align with other studies indicating a significant increase in risk-associated deaths from heart disease and stroke among COVID-19 patients, particularly among ethnic and racial minorities[8]. The heightened mortality risk is intricately linked to the interplay between inflammation and endothelial dysfunction induced by COVID-19. Severe cases trigger a cytokine storm, leading to endothelial injury and thrombotic complications. The study by Lee et al[9]. further elucidates how COVID-19 antibody-mediated cytotoxicity against endothelial cells initiates vascular complications, exacerbating damage in patients with recurrent stroke. The severe stroke presentations in COVID-19 (+) patients[10] can be attributed to COVID-19-induced inflammation and immune dysregulation. Additionally, decreased emergency department visits and delayed hospital admissions due to the pandemic contributed to poor outcomes[11].
While our study revealed that most patients admitted with recurrent acute ischemic stroke and COVID-19 were in the older age group (> 60 years), the adjusted odds for in-hospital mortality were higher across all age groups. Interestingly, the middle-aged group exhibited higher odds compared to other age groups. These results are consistent with findings in other studies that suggested older adults were better protected due to fewer contacts with exposure. For instance, Malmgren et al[12] in Washington State reported a decline in COVID-19 among older individuals and an increase in younger patients, speculating that public warnings targeted those aged 60 and older. In contrast, younger adults had more social interactions. This finding also aligns with studies that hypothesized older adults were better protected[13]. Possible explanations for poorer outcomes in middle-aged include that they may have more subclinical chronic conditions like undiagnosed hypertension and poor metabolic health, leading to worse COVID-19 outcomes[14,15], and this age group may also have a dysregulated immune response leading to increased mortality[16].
Ethnic and racial disparities were evident, with Hispanics and Asian Pacific Islanders showing alarmingly higher odds of mortality. These results align with existing literature highlighting the disproportionate impact of COVID-19 on minority racial and ethnic groups, with hospitalizations being highest among Hispanic/Latino patients[17]. A multicenter case-control study conducted in England and Scotland during the first wave of the pandemic found that Asian ethnicity is strongly linked to COVID-19-related stroke, with the proportion of cases among Asians being more than twice the controls[18]. Annual United States mortality study of 2020 COVID-19-related deaths investigating the impact of socioeconomic position showed that low socioeconomic position and Hispanic ethnicity also stand out as risk factors for COVID-19-related mortality[19,20].
Adjusted subgroup analysis also showed that males had higher in-hospital mortality compared to females. Existing literature shows that there is a more significant burden of stroke deaths among women[21]. However, our study findings showed increased mortality in men compared to women. This finding could have resulted from poorer outcomes from COVID-19 disease among men. These worse outcomes among men suffering from COVID-19 could be attributed to inherent immune differences, an increased prevalence of unhealthy behaviors such as smoking and consuming alcohol, and a higher prevalence of metabolic risk factors among men[22-24].
Our study revealed an elevated prevalence of diabetes and CKD among patients with recurrent stroke and COVID-19. This finding can be attributed to the immunosuppressed nature of these conditions[25]. Diabetic and CKD patients exhibit worsened outcomes due to COVID-19 disease, including higher hospitalization rates, severe pneumonia, acute respiratory distress syndrome, the need for dialysis, and increased mortality[26,27]. Persistent hyperglycemia in diabetes hinders the immune response due to the pro-inflammatory state induced by elevated levels of inflammatory markers such as interleukin-6 and C-reactive protein, aggravating worse clinical outcomes[28]. Concurrently, CKD patients face increased thrombotic risk due to chronic inflammation and uremia[29]. Hypertension, a significant COVID-19 risk factor[30,31], predisposes infected individuals to severe disease through endothelial dysfunction-mediated hypercoagulability[32]. Exploring the impact of the COVID-19 pandemic on the management of chronic conditions reveals a pandemic-induced decline in doctor visits, particularly affecting vulnerable populations[33]. This decline exacerbates comorbidities, raising the risk of recurrent stroke as medication adherence and healthcare continuity wane[34,35]. Our study also highlights the increased risk of recurrent stroke among obese patients, consistent with current literature[36,37]. The pandemic-driven rise in average BMI and obesity prevalence, potentially stemming from decreased physical activity and a sedentary lifestyle, adds to the multifaceted challenges posed by COVID-19[38,39].
Recurrent stroke poses a significant burden on both patients and the healthcare system, with mortality ranging from 11.6% to 25.9% for in-hospital 30-day or 4-year periods[10]. Disability-adjusted life years (DALY) analysis by Hong et al[40] indicates a DALY loss of 3.82 after the index stroke, with an additional 0.84 DALY lost due to recurrent stroke. The average healthcare cost per person for stroke, including inpatient care, rehabilitation, and follow-up, is estimated at USD 140048[41]. Our study reports median in-hospital costs for recurrent stroke and COVID-19 at $80888, $28226 higher than those without COVID-19. Patients in the COVID-19 (+) cohort had a longer length of stay at seven days compared to those in the COVID-19 (-) cohort (3 days).
Given this significant burden, our study has many future clinical implications. Rigorous management of risk factors and comorbid conditions is necessary. Timely screening, healthy behaviors, and equitable healthcare access are pivotal in reducing the disparities found in our study. Telemedicine and tailored prevention plans are crucial for achieving continuity of care and must be further explored for less severe cases.
Through this study, we highlighted various risk factors for poor outcomes in patients admitted due to recurrent stroke and COVID-19. However, it is imperative to acknowledge the retrospective nature of our study and its inherent limitations. The observational nature of the study limits control over all potential confounders. Firstly, there might be administrative coding errors in the NIS database, which could over or underestimate COVID-19 and recurrent strokes. Variability in documentation and coding of comorbidities and outcomes across different healthcare facilities could influence the results. Secondly, our study only focuses on data from hospitalized patients, introducing potential sampling bias, as it overlooks undiagnosed or milder cases of COVID-19 not requiring hospitalization. Lack of outpatient data and long-term COVID-19 symptoms monitoring might impact results. An additional constraint of our study, stemming from its reliance on the NIS database for 2020, is the absence of vaccination status data for the subjects early in the pandemic. This limitation is particularly critical when assessing the potential mitigating impact of COVID-19 vaccines on the severe presentation of stroke, as demonstrated by Jiang et al[42], who found an association between even partial vaccination and a lower risk of major adverse cardiovascular events post-COVID-19 infection. Thirdly, data on the incidence of stroke among various ethnicities could have been influenced by reporting bias, as previous studies have shown a higher risk of stroke among African Americans. Finally, the data was not subclassified based on mechanisms of previous stroke, such as large vessel atherosclerosis or cardioembolic stroke. This subclassification is crucial for determining outcomes based on underlying mechanisms, and future prospective studies need to focus on incorporating this data to improve the management of these patients. In this context, future studies should focus on these limitations, and further prospective studies should be done with vaccination status data to understand the efficacy of vaccines in preventing severe manifestations and improving vaccination rates. Also, studies need to be done to understand the long-term implications of COVID-19 disease on patients with a history of stroke or TIA.
Our study shows increased in-hospital mortality after recurrent stroke and COVID-19, especially among the age group 45–64 years, Hispanics, and males. Given these findings, it is imperative to monitor risk factors such as diabetes rigorously, consistently screen them with HbA1c tests, and maintain strict glucose control, as such patients are at significant risk for recurrent stroke. Ensuring these patients stay compliant with secondary prevention strategies such as statin and antiplatelet agent use is paramount. Ethnic disparities evident in our study might be due to the lack of access and increased disease burden in these minority populations. Possible ways to reduce disparities include implementing evidence-based practices system-wide with quality improvement initiatives and encouraging best practices. New policies must address these disparities and reinforce existing policies to improve health equity among all ethnicities. Further prospective studies are essential to unraveling the mechanisms underlying the long-term consequences of COVID-19, particularly stroke incidence. Designing a comprehensive timeline for stroke occurrences and post-Covid-19 infection will contribute to a deeper understanding of this phenomenon. As more data on the long-term sequelae of COVID-19 evolves, the risk of stroke and other thromboembolic phenomena could be better understood.
1. | Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R, Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP, Thacker EL, Virani SS, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Martin SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93-e621. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1045] [Cited by in F6Publishing: 1303] [Article Influence: 1303.0] [Reference Citation Analysis (0)] |
2. | Modig K, Talbäck M, Ziegler L, Ahlbom A. Temporal trends in incidence, recurrence and prevalence of stroke in an era of ageing populations, a longitudinal study of the total Swedish population. BMC Geriatr. 2019;19:31. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
3. | Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52:e364-e467. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 519] [Cited by in F6Publishing: 1161] [Article Influence: 387.0] [Reference Citation Analysis (0)] |
4. | Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42:1489-1494. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 372] [Cited by in F6Publishing: 427] [Article Influence: 32.8] [Reference Citation Analysis (0)] |
5. | Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32:2735-2740. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 774] [Cited by in F6Publishing: 817] [Article Influence: 35.5] [Reference Citation Analysis (0)] |
6. | Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, Calleja P, Ostos F, González-Ortega G, Fuentes B, Alonso de Leciñana M, Díez-Tejedor E, García-Madrona S, Masjuan J, DeFelipe A, Turc G, Gonçalves B, Domigo V, Dan GA, Vezeteu R, Christensen H, Christensen LM, Meden P, Hajdarevic L, Rodriguez-Lopez A, Díaz-Otero F, García-Pastor A, Gil-Nuñez A, Maslias E, Strambo D, Werring DJ, Chandratheva A, Benjamin L, Simister R, Perry R, Beyrouti R, Jabbour P, Sweid A, Tjoumakaris S, Cuadrado-Godia E, Campello AR, Roquer J, Moreira T, Mazya MV, Bandini F, Matz K, Iversen HK, González-Duarte A, Tiu C, Ferrari J, Vosko MR, Salzer HJF, Lamprecht B, Dünser MW, Cereda CW, Quintero ÁBC, Korompoki E, Soriano-Navarro E, Soto-Ramírez LE, Castañeda-Méndez PF, Bay-Sansores D, Arauz A, Cano-Nigenda V, Kristoffersen ES, Tiainen M, Strbian D, Putaala J, Lip GYH. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. Stroke. 2020;51:e254-e258. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 128] [Cited by in F6Publishing: 178] [Article Influence: 44.5] [Reference Citation Analysis (0)] |
7. | Merkler AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, Lantos J, Schenck EJ, Goyal P, Bruce SS, Kahan J, Lansdale KN, LeMoss NM, Murthy SB, Stieg PE, Fink ME, Iadecola C, Segal AZ, Cusick M, Campion TR Jr, Diaz I, Zhang C, Navi BB. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. JAMA Neurol. 2020;77:1-7. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 416] [Cited by in F6Publishing: 417] [Article Influence: 104.3] [Reference Citation Analysis (0)] |
8. | Sidney S, Lee C, Liu J, Khan SS, Lloyd-Jones DM, Rana JS. Age-Adjusted Mortality Rates and Age and Risk-Associated Contributions to Change in Heart Disease and Stroke Mortality, 2011-2019 and 2019-2020. JAMA Netw Open. 2022;5:e223872. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis (0)] |
9. | Lee MH, Perl DP, Steiner J, Pasternack N, Li W, Maric D, Safavi F, Horkayne-Szakaly I, Jones R, Stram MN, Moncur JT, Hefti M, Folkerth RD, Nath A. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022;145:2555-2568. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 105] [Article Influence: 52.5] [Reference Citation Analysis (0)] |
10. | Ferrone SR, Sanmartin MX, Ohara J, Jimenez JC, Feizullayeva C, Lodato Z, Shahsavarani S, Lacher G, Demissie S, Vialet JM, White TG, Wang JJ, Katz JM, Sanelli PC. Acute ischemic stroke outcomes in patients with COVID-19: a systematic review and meta-analysis. J Neurointerv Surg. 2024;16:333-341. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
11. | Tong X, King SMC, Asaithambi G, Odom E, Yang Q, Yin X, Merritt RK. COVID-19 Pandemic and Quality of Care and Outcomes of Acute Stroke Hospitalizations: the Paul Coverdell National Acute Stroke Program. Prev Chronic Dis. 2021;18:E82. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
12. | Malmgren J, Guo B, Kaplan HG. Continued proportional age shift of confirmed positive COVID-19 incidence over time to children and young adults: Washington State March-August 2020. PLoS One. 2021;16:e0243042. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
13. | O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, Fontanet A, Cauchemez S, Salje H. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140-145. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 513] [Cited by in F6Publishing: 673] [Article Influence: 168.3] [Reference Citation Analysis (0)] |
14. | Elias S, Dadi TK. Prevalence of Undiagnosed Hypertension and Associated Factors among Adults in Mizan-Aman Town, Bench Sheko Zone, Southwest Ethiopia: A Community-Based Cross-Sectional Study. Adv Med. 2023;2023:2746284. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
15. | Boro B, Banerjee S. Decomposing the rural-urban gap in the prevalence of undiagnosed, untreated and under-treated hypertension among older adults in India. BMC Public Health. 2022;22:1310. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
16. | Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the Ageing Immune System. Nat Aging. 2021;1:769-782. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 219] [Cited by in F6Publishing: 180] [Article Influence: 60.0] [Reference Citation Analysis (0)] |
17. | Romano SD, Blackstock AJ, Taylor EV, El Burai Felix S, Adjei S, Singleton CM, Fuld J, Bruce BB, Boehmer TK. Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021;70:560-565. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 81] [Cited by in F6Publishing: 151] [Article Influence: 50.3] [Reference Citation Analysis (0)] |
18. | Perry RJ, Smith CJ, Roffe C, Simister R, Narayanamoorthi S, Marigold R, Willmot M, Dixit A, Hassan A, Quinn TJ, Ankolekar S, Zhang L, Banerjee S, Ahmed U, Padmanabhan N, Ferdinand P, McGrane F, Banaras A, Marks IH, Werring DJ; SETICOS collaborators. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. J Neurol Neurosurg Psychiatry. 2021;92:242-248. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 44] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis (0)] |
19. | Pathak EB, Menard JM, Garcia RB, Salemi JL. Joint Effects of Socioeconomic Position, Race/Ethnicity, and Gender on COVID-19 Mortality among Working-Age Adults in the United States. Int J Environ Res Public Health. 2022;19. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis (0)] |
20. | Robinson DJ, Stanton R, Sucharew H, Alwell K, Haverbusch M, De Los Rios La Rosa F, Ferioli S, Coleman E, Jasne A, Mackey J, Star M, Mistry EA, Demel S, Slavin S, Walsh K, Woo D, Kissela B, Kleindorfer DO. Racial Disparities in Stroke Recurrence: A Population-Based Study. Neurology. 2022;99:e2464-e2473. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 4] [Reference Citation Analysis (0)] |
21. | Rexrode KM, Madsen TE, Yu AYX, Carcel C, Lichtman JH, Miller EC. The Impact of Sex and Gender on Stroke. Circ Res. 2022;130:512-528. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 159] [Article Influence: 79.5] [Reference Citation Analysis (0)] |
22. | Fabião J, Sassi B, Pedrollo EF, Gerchman F, Kramer CK, Leitão CB, Pinto LC. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz J Med Biol Res. 2022;55:e11711. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis (0)] |
23. | Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339-344. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 488] [Cited by in F6Publishing: 414] [Article Influence: 103.5] [Reference Citation Analysis (0)] |
24. | Manaf MRA, Nawi AM, Tauhid NM, Othman H, Rahman MRA, Yusoff HM, Safian N, Ng PY, Manaf ZA, Kadir NBA, Yanasegaran K, Basir SMA, Ramakrishnappa S, Ganasegeran K. Prevalence of metabolic syndrome and its associated risk factors among staffs in a Malaysian public university. Sci Rep. 2021;11:8132. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis (0)] |
25. | Pecly IMD, Azevedo RB, Muxfeldt ES, Botelho BG, Albuquerque GG, Diniz PHP, Silva R, Rodrigues CIS. COVID-19 and chronic kidney disease: a comprehensive review. J Bras Nefrol. 2021;43:383-399. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
26. | Chung EYM, Palmer SC, Natale P, Krishnan A, Cooper TE, Saglimbene VM, Ruospo M, Au E, Jayanti S, Liang A, Jie Deng DJ, Chui J, Higgins GY, Tong A, Wong G, Teixeira-Pinto A, Hodson EM, Craig JC, Strippoli GFM. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2021;78:804-815. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 60] [Article Influence: 20.0] [Reference Citation Analysis (0)] |
27. | Singh AK, Khunti K. COVID-19 and Diabetes. Annu Rev Med. 2022;73:129-147. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis (0)] |
28. | Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: A bidirectional relationship. Clin Investig Arterioscler. 2021;33:151-157. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 62] [Article Influence: 15.5] [Reference Citation Analysis (0)] |
29. | Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, Wong CX, Sarnak M, Cheung M, Herzog CA, Johansen KL, Reinecke H, Sood MM. Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference. Stroke. 2021;52:e328-e346. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 50] [Article Influence: 16.7] [Reference Citation Analysis (0)] |
30. | Muhamad SA, Ugusman A, Kumar J, Skiba D, Hamid AA, Aminuddin A. COVID-19 and Hypertension: The What, the Why, and the How. Front Physiol. 2021;12:665064. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis (0)] |
31. | Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017;956:511-540. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 247] [Cited by in F6Publishing: 121] [Article Influence: 15.1] [Reference Citation Analysis (0)] |
32. | Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, Navalesi P, Simioni P. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost. 2020;120:998-1000. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 343] [Cited by in F6Publishing: 413] [Article Influence: 103.3] [Reference Citation Analysis (1)] |
33. | Czeisler MÉ, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, Ali N, McMillan H, Wiley JF, Weaver MD, Czeisler CA, Rajaratnam SMW, Howard ME. Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns - United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1250-1257. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 533] [Cited by in F6Publishing: 924] [Article Influence: 231.0] [Reference Citation Analysis (0)] |
34. | Egan BM, Sutherland SE, Macri CI, Deng Y, Gerelchuluun A, Rakotz MK, Campbell SV. Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults. JAMA Netw Open. 2022;5:e2247787. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
35. | Kronish IM, Diefenbach MA, Edmondson DE, Phillips LA, Fei K, Horowitz CR. Key barriers to medication adherence in survivors of strokes and transient ischemic attacks. J Gen Intern Med. 2013;28:675-682. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis (0)] |
36. | Modin D, Claggett B, Sindet-Pedersen C, Lassen MCH, Skaarup KG, Jensen JUS, Fralick M, Schou M, Lamberts M, Gerds T, Fosbøl EL, Phelps M, Kragholm KH, Andersen MP, Køber L, Torp-Pedersen C, Solomon SD, Gislason G, Biering-Sørensen T. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation. 2020;142:2080-2082. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 76] [Cited by in F6Publishing: 149] [Article Influence: 37.3] [Reference Citation Analysis (0)] |
37. | Horn JW, Feng T, Mørkedal B, Strand LB, Horn J, Mukamal K, Janszky I. Obesity and Risk for First Ischemic Stroke Depends on Metabolic Syndrome: The HUNT Study. Stroke. 2021;52:3555-3561. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
38. | Restrepo BJ. Obesity Prevalence Among U.S. Adults During the COVID-19 Pandemic. Am J Prev Med. 2022;63:102-106. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 55] [Article Influence: 27.5] [Reference Citation Analysis (0)] |
39. | Joundi RA, Patten SB, Williams JVA, Smith EE. Association Between Excess Leisure Sedentary Time and Risk of Stroke in Young Individuals. Stroke. 2021;52:3562-3568. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
40. | Hong KS, Saver JL, Kang DW, Bae HJ, Yu KH, Koo J, Han MK, Cho YJ, Park JM, Lee BC. Years of optimum health lost due to complications after acute ischemic stroke: disability-adjusted life-years analysis. Stroke. 2010;41:1758-1765. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
41. | Johnson BH, Bonafede MM, Watson C. Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke. Clinicoecon Outcomes Res. 2016;8:53-61. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis (0)] |
42. | Jiang J, Chan L, Kauffman J, Narula J, Charney AW, Oh W, Nadkarni G; N3C Consortium. Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection. J Am Coll Cardiol. 2023;81:928-930. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis (0)] |